Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder ("BED") were presented at the American Psychiatric Association ("APA") Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

“BED is one of the major causes of obesity and the most chronic and common of all eating disorders. Our intranasal naloxone is a truly differentiated treatment because it addresses harmful eating behavior, and inclusion in DSM-5 should help with reimbursement of therapies for BED.”

BED has been added to the fifth edition of the APA's Diagnostic and Statistical Manual of Mental Disorders ("DSM-5"), which was launched at the APA Annual Meeting. DSM-5 is used by clinicians and researchers to diagnose and classify mental disorders in order to improve diagnoses, treatment, and research. This manual is the product of more than 10 years of effort by hundreds of international experts in all aspects of mental health. DSM-5 diagnostic criteria are concise and explicit, intended to facilitate an objective assessment of symptom presentations in a variety of clinical settings from inpatient to primary care. BED is defined in the DSM-5 chapter on Feeding and Eating Disorders as a diagnosis for individuals who experience persistent, recurrent episodes of overeating, marked by loss of control and significant clinical distress. The chapter also includes changes in the requirements for diagnosis of anorexia nervosa and bulimia nervosa, two potential additional indications for Lightlake's treatment.

"We are very pleased to see that Binge Eating Disorder has been added to the APA's DSM-5," commented Dr. Roger Crystal, Chief Executive Officer of Lightlake. "BED is one of the major causes of obesity and the most chronic and common of all eating disorders. Our intranasal naloxone is a truly differentiated treatment because it addresses harmful eating behavior, and inclusion in DSM-5 should help with reimbursement of therapies for BED."